George Sakoulas

Chlorhexidine Exerts Selective Pressure on Daptomycin Susceptibility in VRE

Vancomycin-resistant Enterococcus faecium (VRE) is problematic when intrinsic resistance and host immunocompromise have produced deep-seated or

Vancomycin MIC in MSSA: A Virulence Marker?

Vancomycin has been the cornerstone of empiric antistaphylococcal therapy since prevalence of methicillin-resistant Staphylococcus aureus (MRSA)

Meropenem plus Ceftolozane-Tazobactam Synergy Against XDR

Treatment of infections caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa presents a significant clinical challenge. Owing to a paucity

Do Topical Antibiotics Play a Role in Selecting Multidrug-Resistant Pathogens?

The coselection of multidrug-resistant phenotypes has been well documented among systemic antibiotics, but little attention has been paid to topical

Invasive Procedures Are Associated with Bacterial Endocarditis

Invasive diagnostic or therapeutic medical procedures may trigger infective endocarditis caused by transient bacteremia. Whether antimicrobial

Increasing Vancomycin's Potency with Simple Chemical Modifications

Vancomycin is a commonly prescribed antibiotic because of methicillin-resistant Staphylococcus aureus (MRSA) emergence in the 1980s. With increased use

Increasing Intraosteoblastic Activity of Daptomycin with Beta-Lactams

The persistence of Staphylococcus aureus within osteoblasts suggests that therapies having intracellular activity may reduce relapses. The potent

A New Antimicrobial Susceptibility Paradigm

Results of antimicrobial susceptibility testing provide fundamental guidance for clinicians prescribing antimicrobial therapy. Increasing evidence

Delafloxacin Approved for Treatment of Skin Infections

On June 19, 2017, the FDA announced approval of delafloxacin (Baxdela) for treatment of acute bacterial skin and skin-structure infections (ABSSSIs)